Patents by Inventor Paul Manley

Paul Manley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080039440
    Abstract: The invention relates to novel compounds of Formula I: wherein p is 1, 2 or 3; n is 0, 1, 2 or 3; m is 0, 1, 2 or 3; A is CRc, S, NRc or O, where Rc is H or lower alkyl; X, Y and Z are each independently selected from N or C—R3, wherein at least two of X, Y and Z are N; and each Ra is independently selected from hydrogen and lower-alkyl; each Rb is hydrogen or lower-alkyl; G is a group Ar or represents CN or unsubstituted or substituted lower alkyl; Ar is a saturated or unsaturated cyclic group, which is substituted or unsubstituted and maybe a five or six membered monocyclic or a 8, 9, 10, 11 or 12 membered bicyclic or tricyclic ring and may contain 0, 1, 2 or 3 heteroatoms selected from O, N and S; and wherein the radicals have R1, R2, R3 and R4 have the meanings as defined herein, to salts, esters, N-oxides or prodrugs thereof; and their use in the treatment of protein kinase dependent diseases, their use in the manufacture of pharmaceutical compositions for use in the treatment of said diseases
    Type: Application
    Filed: September 27, 2005
    Publication date: February 14, 2008
    Inventors: Guido Bold, Giorgio Caravatti, Andreas Floersheimer, Pascal Furet, Paul Manley, Carole Pissot Soldermann, Andrea Vaupel
  • Publication number: 20070265292
    Abstract: The invention relates to N-phenyl-2-pyrimidine-amine derivatives of formula I wherein the substituents are defined as indicated in the description, to processes for the preparation thereof, to medicaments comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.
    Type: Application
    Filed: July 26, 2007
    Publication date: November 15, 2007
    Inventors: Hans Buerger, Giorgio Caravatti, Juerg Zimmermann, Paul Manley, Werner Breitenstein, Margaret Cudd
  • Publication number: 20070149539
    Abstract: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamdio]-2-methylphenyl }-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N- {5- [4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl }-4-(3-pyridyl)-2-pyrimidine-amine.
    Type: Application
    Filed: February 28, 2007
    Publication date: June 28, 2007
    Inventors: Nicholas Donato, Doriano Fabbro, Paul Manley, Jurgen Mestan, Markus Warmuth, Michael Hallek, Moshe Talpaz, Ji Wu
  • Publication number: 20070093506
    Abstract: The invention relates to compounds of formula wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.
    Type: Application
    Filed: December 1, 2006
    Publication date: April 26, 2007
    Inventors: Werner Breitenstein, Pascal Furet, Sandra Jacob, Paul Manley
  • Publication number: 20070027167
    Abstract: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamdio]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.
    Type: Application
    Filed: September 5, 2006
    Publication date: February 1, 2007
    Inventors: Nicholas Donato, Doriano Fabbro, Paul Manley, Jurgen Mestan, Markus Warmuth, Michael Hallek, Moshe Talpaz, Ji Wu
  • Publication number: 20060223818
    Abstract: The invention relates to N-phenyl-2-pyrimidine-amine derivatives of formula I wherein the substituents are defined as indicated in the description, to processes for the preparation thereof, to medicaments comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.
    Type: Application
    Filed: June 7, 2006
    Publication date: October 5, 2006
    Inventors: Hans Buerger, Giorgio Caravatti, Juerg Zimmermann, Paul Manley, Werner Breitenstein, Margaret Cudd
  • Publication number: 20060217388
    Abstract: The invention relates to the treatment of leukemias with an inhibitor of the activity of VEGF receptor tyrosine kinase of the formula I, the substituents being defined in the specification; as well as to new phthalazine derivatives; processes for the preparation thereof; the application thereof in a process for the treatment of the human or animal body; the use thereof for the treatment of a disease, especially a disease caused by ocular neovascularization, such as age-related macula degeneration or diabetic retinopathy, or other diseases that respond to the inhibition of tyrosine kinases, such as a proliferative disease; a method for the treatment of such disease in mammals; and the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment especially of a disease as mentioned above.
    Type: Application
    Filed: May 26, 2006
    Publication date: September 28, 2006
    Inventors: Guido Bold, Janet King, Jorg Frei, Richard Heng, Paul Manley, Bernhard Wietfeld, Jeanette Wood
  • Publication number: 20060178409
    Abstract: The invention relates to anthranilic acid amide derivatives of formula I, wherein R1 represents H or lower alkyl, R2 represents H or lower alkyl, R3 represents perfluoro lower alkyl, and X is O or S, or an N-oxide or a tautomer thereof, to salts of such anthranilic acid amides, their N-oxides and their tautomers; processes for the preparation thereof, the application thereof for the treatment of the human or animal body, the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment especially of a neoplastic disease, such as a tumor disease, of retinopathy or age-related macular degeneration; a method for the treatment of such a disease in animals, especially in humans, and the use of such a compound—alone or in combination with one or more other pharmaceutically active compounds—for the manufacture of a pharmaceutical preparation for the treatment of a neoplastic disease, of retinopathy or age-related macular degeneration.
    Type: Application
    Filed: March 14, 2006
    Publication date: August 10, 2006
    Inventors: Guido Bold, Pascal Furet, Paul Manley
  • Publication number: 20060167015
    Abstract: The invention relates to compounds of formula wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.
    Type: Application
    Filed: July 4, 2003
    Publication date: July 27, 2006
    Inventors: Werner Breitenstein, Pascal Furet, Sandra Jacob, Paul Manley
  • Publication number: 20060142577
    Abstract: The invention relates to novel substituted N-(3-benzoylaminophenyl)-4-pyridyl-2-pyrimidinamine derivatives, processes for the preparation thereof, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, and a method for the treatment of such a disease.
    Type: Application
    Filed: September 26, 2003
    Publication date: June 29, 2006
    Inventors: Paul Manley, Werner Breitenstein, Sandra Jacob, Pascal Furet
  • Publication number: 20060128684
    Abstract: The present invention relates to new anthranilic acid amide derivatives, processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body, the use thereof—alone or in combination with one or more other pharmaceutically active compounds.
    Type: Application
    Filed: December 11, 2003
    Publication date: June 15, 2006
    Inventors: Guido Bold, Pascal Furet, Paul Manley
  • Publication number: 20060074112
    Abstract: Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1 is aryl; R2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R2 cannot represent 2-phthalimidyl, and in case of Y?SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each, other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.
    Type: Application
    Filed: October 20, 2005
    Publication date: April 6, 2006
    Inventors: Karl-Heinz Altmann, Guido Bold, Pascal Furet, Paul Manley, Jeanette Wood, Stefano Ferrari, Francesco Hofmann, Jurgen Mestan, Andreas Huth, Martin Kruger, Dieter Seidelmann, Andreas Menrad, Martin Haberey, Karl-Heinz Thierauch
  • Publication number: 20060074094
    Abstract: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Btk kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.
    Type: Application
    Filed: November 22, 2005
    Publication date: April 6, 2006
    Inventors: Nicholas Donato, Doriano Fabbro, Paul Manley, Jurgen Mestan, Markus Warmuth, Michael Hallek, Moshe Talpaz, Ji Wu
  • Publication number: 20060030017
    Abstract: The present invention concerns c-Abl, in particular, the three-dimensional structure of c-Abl containing an active DFG conformation. The atomic coordinates of c-Abl possessing this active DFG motif complexed with a specific ligand are also provided.
    Type: Application
    Filed: March 22, 2005
    Publication date: February 9, 2006
    Inventors: Gabriele Fendrich, Sandra Jacob, Anthony Klon, Paul Manley
  • Publication number: 20050209452
    Abstract: The invention relates to N-phenyl-2-pyrimidine-amine derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.
    Type: Application
    Filed: January 22, 2003
    Publication date: September 22, 2005
    Inventors: Klaus Bornsen, Peter End, Gerhard Gross, Ulrike Pfaar, Paul Manley, Jurg Zimmermann
  • Publication number: 20050186313
    Abstract: A method for decorating fruit with a design wherein the design is printed on an edible sheet or an edible film with a peelable backing. The printed design is then attached to fruit which is coated with an edible coating. If an edible sheet is used, then the edible sheet may be the same color as the edible coating.
    Type: Application
    Filed: February 23, 2004
    Publication date: August 25, 2005
    Inventor: Paul Manley
  • Publication number: 20050176711
    Abstract: The invention relates to the treatment of an inflammatory disease, especially an inflammatory rheumatoid or rheumatic disease, and/or pain with an inhibitor of the activity of VEGF receptor tyrosine kinase of the formula I, wherein r is 0 to 2, n is 0 to 3 R1 and R2 a) are independently in each case a lower alkyl; b) together form a bridge of subformula I*, wherein the bond is achieved via the two terminal C atoms and m is 0 to 4, or c) together form a bridge of subformula I**, wherein one or two of the ring members T1, T2, T3 and T4 are nitrogen, and the others are in each case CH, and the bond is achieved via atoms T1 and T4; G is —C(?O)—, —CHF—, —CF2—, lower alkylene, C2-C6alkenylene, lower alkylene or C3-C6alkenylene substituted by acyloxy or hydroxy, —CH2—O—, —CH2S—, —CH2—NH—, —CH2—O—CH2—, —CH2—S—CH2—, —CH2—NH—CH2—, oxa (—O—), thia (—S—), imino (—NH—), —CH2—O—CH2—, —CH2S—CH2— or —CH2—NH—CH2—; A, B, D, E and T are independently N or CH subject to the proviso that at least one and not more t
    Type: Application
    Filed: April 5, 2005
    Publication date: August 11, 2005
    Inventors: Guido Bold, Janet King, Joerg Frei, Richard Heng, Paul Manley, Bernhard Wietfeld, Jeanette Wood
  • Publication number: 20050096356
    Abstract: The invention relates to anthranilic acid amide derivatives of formula (I), wherein R1 represents H or lower alkyl, R2 represents H or lower alkyl, R3 represents perfluoro lower alkyl, and X is O or S, or an N-oxide or a tautomer thereof, to salts of such anthranilic acid amides, their N-oxides and their tautomers; processes for the preparation thereof, the application thereof for the treatment of the human or animal body, the use thereof—alone or in combination with one or more other pharmaceutically active compounds—for the treatment especially of a neoplastic disease, such as a tumor disease, of retinopathy or age—related macular degeneration; a method for the treatment of such a disease in animals, especially in humans, and the use of such a compound—alone or in combination with one or more other pharmaceutically active compounds—for the manufacture of a pharmaceutical preparation for the treatment of a neoplastic disease, of retinopathy or age-related macular degeneration.
    Type: Application
    Filed: November 7, 2002
    Publication date: May 5, 2005
    Inventors: Guido Bold, Pascal Furet, Paul Manley
  • Publication number: 20050020570
    Abstract: The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.
    Type: Application
    Filed: October 29, 2002
    Publication date: January 27, 2005
    Inventors: James Griffin, Paul Manley
  • Patent number: D244869
    Type: Grant
    Filed: September 8, 1976
    Date of Patent: June 28, 1977
    Inventors: Paul Manley, Darlene Johnson